Female libido med Addyi hits U.S. pharmacies; Sanofi launches PCSK9 med Praluent in U.K.;

> Sprout Pharmaceuticals rolled out the controversial female libido drug Addyi on Saturday, and analysts are saying that safety issues with the med could spur development of better follow-up drugs. Report

> Sanofi ($SNY) and Regeneron ($REGN) rolled out their cholesterol-fighting PCSK9 drug Praluent in the U.K., going up against Amgen's ($AMGN) Repatha, which launched there last month. Report

> Drugmakers prevailed in their latest fight against 340B hospital discounts on orphan drugs in nonorphan indications. Report

> Johnson & Johnson ($JNJ) won its first lawsuit over Tylenol and its potential links to liver damage; the company faces more than 200 similar claims of a design defects in the popular pain reliever. Report

And Finally... The Novartis ($NVS) cancer drug Tasigna delivered "meaningful clinical improvements" in 10 of 11 Parkinson's disease patients in an early-stage trial. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.

AbbVie and Allergan's merger may create the fourth-largest drugmaker in the world, but it could also create opportunities for other drugmakers.